Related Experiment Video

Updated: Jun 26, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer

Bixiang Zhang1, Sunil K Halder, Sanguo Zhang

  • 1Departments of Surgery and Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, 1161 21st Avenue South, Nashville, TN 37232, USA.

Cancer Letters
|January 17, 2009
PubMed

Insights

A novel dual kinase inhibitor, LY2109761, targeting TGF-beta receptors effectively blocks tumor growth and metastasis in colorectal cancer models. This suggests its potential as a therapeutic strategy for advanced colorectal cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Transforming growth factor-beta (TGF-beta) paradoxically promotes tumor growth, invasion, and metastasis in advanced colorectal cancer, despite its primary tumor suppressor role.
  • Targeting TGF-beta signaling pathways is a potential therapeutic strategy for colorectal cancer, but the in vivo effects of TGF-beta receptor kinase inhibitors are not well understood.

Purpose of the Study:

  • To investigate the effects of a novel dual kinase inhibitor, LY2109761, targeting TGF-beta type I and type II receptors, on colorectal carcinogenesis in vivo.
  • To evaluate the therapeutic potential of LY2109761 in preclinical models of colorectal cancer metastasis.

Main Methods:

  • Utilized CT26 colon adenocarcinoma cells with K-Ras mutation to assess LY2109761's inhibition of TGF-beta-mediated Smad and non-Smad pathways.
  • Evaluated the impact of LY2109761 on cell migration, invasion, and tumorigenicity in vitro.
  • Assessed the effect of LY2109761 on liver metastases and survival in an experimental metastasis model.

Main Results:

  • LY2109761 effectively inhibited TGF-beta-mediated activation of Smad and non-Smad signaling pathways in CT26 cells.
  • The inhibitor attenuated the oncogenic effects of TGF-beta, reducing cell migration, invasion, and tumorigenicity.
  • LY2109761 significantly decreased liver metastases and prolonged survival in the experimental metastasis model.

Conclusions:

  • The dual kinase inhibitor LY2109761 demonstrates significant anti-metastatic and anti-tumorigenic effects in preclinical colorectal cancer models.
  • LY2109761 targets key TGF-beta signaling pathways implicated in colorectal cancer progression.
  • These findings highlight the therapeutic potential of LY2109761 for treating metastatic colorectal cancer.

More Related Videos

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...